prednisolone sodium phosphate injection usp süstelahus
swiss parenterals pvt ltd - prednisoloon - süstelahus - 25mg 1ml 1ml 5tk
hypnorex retard tablett
sanofi-synthelabo - liitium - tablett - 400mg 100tk
ampicillin sodium süstelahuse pulber
cspc zhongnuo pharmaceutical (shijiazhuang) - ampitsilliin - süstelahuse pulber - 1000mg 50tk
phenobarbital sodium süstelahus
sterop overseas s.a. laboratories - fenobarbitaal - süstelahus - 100mg 1ml 1ml 100tk
calcium edetate sodium serb süstelahus
laboratoires serb - naatriumkaltsiumedetaat - süstelahus - 500mg 10ml 10tk
lithium carbonicum slovakofarma tablett
saneca pharmaceuticals a.s. - liitium - tablett - 300mg 100tk
heparin sodium süstelahus
c p pharmaceuticals limited - naatriumhepariin - süstelahus - 5000rÜ 1ml 5ml 10tk
minims fluorescein sodium 1% silmatilgad, lahus
laboratoire chauvin s.a. - fluorestseiin - silmatilgad, lahus - 10mg 1ml 0.5ml 20tk
heparine sodium sterop süstelahus
sterop overseas s.a. laboratories - naatriumhepariin - süstelahus - 5000rÜ 1ml 5ml 10tk
zercepac
accord healthcare s.l.u. - trastuzumab - breast neoplasms; stomach neoplasms - antineoplastilised ained - breast cancermetastatic breast cancer zercepac is indicated for the treatment of adult patients with her2 positive metastatic breast cancer (mbc):as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. eelnev keemiaravi peab olema kantud vähemalt anthracycline ja taxane välja arvatud juhul, kui patsientidele ei sobi nende ravi. hormooni retseptori positiivne patsientidel peab olema ebaõnnestunud hormoonravi, välja arvatud juhul, kui patsientidele ei sobi nende ravi. in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. koos docetaxel raviks nendel patsientidel, kes ei ole saanud keemiaravi oma metastaatilise haiguse. kombinatsioonis aromataasi inhibiitoriga ravi postmenopausis patsientidel hormoon-retseptor positiivne mbc, mis ei ole varem ravitud trastuzumab. early breast cancer zercepac is indicated for the treatment of adult patients with her2 positive early breast cancer (ebc). pärast operatsiooni, kemoteraapiat (neoadjuvant-või abiaine) ja kiiritusravi (kui on kohaldatav). järgmised abiaine keemiaravi koos doxorubicin ja tsüklofosfamiidiga kombinatsioonis paclitaxel või docetaxel. koos abiaine keemiaravi, mis koosneb docetaxel ja carboplatin. in combination with neoadjuvant chemotherapy followed by adjuvant zercepac therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter. zercepac should only be used in patients with metastatic or early breast cancer whose tumours have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay. metastatic gastric cancer zercepac in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with her2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. zercepac should only be used in patients with metastatic gastric cancer (mgc) whose tumours have her2 overexpression as defined by ihc2+ and a confirmatory sish or fish result, or by an ihc 3+ result. täpseid ja valideeritud analüüsi meetodeid tuleks kasutada.